**Antimicrobial Use and Resistance (AUR): Microbiology Laboratory Data**

**Monthly Electronic Upload Specification Tables**

*These data will be collected in an aggregate monthly electronic file transfer from the facility to NHSN via Clinical Document Architecture (CDA).*

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Page 1 of 2 | | | | | | |
| **Table 1. CDA File Descriptors** | | *These data elements will be transmitted with each month’s report.* | | | | |
| **Variable Name** | Description of Variable | | | | | |
| orgid | NHSN Facility ID number | | | | | |
| location | NHSN location code | | | | | |
| month | Denominator month | | | | | |
| year | Denominator year | | | | | |
| Application OID | Vendor software ID number | | | | | |
| SDS validation ID | ID provided by NHSN Team confirming vendor software passed validation | | | | | |
| **Table 2. Isolate Event Details** | | *These data elements will be transmitted with each month’s report.* | | | | |
| **Variable Name** | Description of Variable | | | | **Examples** | |
| eventID | Event ID number | | | |  | |
| specimenDate | Date specimen collected | | | |  | |
| specimenSource | Specimen Source | | | | Blood, lower respiratory, urine, cerebral spinal fluid | |
| specBodySite | Specimen Body Site/System | | | |  | |
| isolateID | Isolate identifier | | | |  | |
| facilityAdmitDate | Date admitted to facility | | | |  | |
| admitStatus | Was patient admitted to an inpatient location | | | | Y/N | |
| specimenLoc | Location of specimen collection | | | |  | |
| pathogen | Identified pathogen | | | |  | |
| PtDOB | Patient date of birth | | | |  | |
| PtGender | Patient gender | | | |  | |
| PtID | Patient ID number | | | |  | |
| **Table 2a. List of Eligible Pathogens** | | | | *This is the list of pathogens that will be accepted into NHSN as part of the antimicrobial resistance reporting. Complete list of accepted is found in the NHSN IDM Workbook.* | | |
| Acinetobacter species | | | Citrobacter koseri | | | Morganella morganii |
| Candida albicans | | |  | | | Proteus mirabilis |
| Candida auris | | | Enterobacter species | | | Proteus penneri |
| Candida glabrata | | | Enterococcus faecalis | | | Proteus vulgaris |
| Candida parapsilosis | | | Enterococcus faecium | | | Pseudomonas aeruginosa |
| Candida tropicalis | | | Enterococcus species | | | Serratia marcescens |
| Citrobacter amalonaticus | | | Escherichia coli | | | Staphylococcus aureus |
| Citrobacter braakii | | | Klebsiella aerogenes | | | Stenotrophomonas maltophilia |
| Citrobacter freundii | | | Klebsiella oxytoca | | | Streptococcus agalactiae |
| Citrobacter freundii complex | | | Klebsiella pneumoniae | | | Streptococcus pneumoniae |
| **Assurance of Confidentiality:** The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).  Public reporting burden of this collection of information is estimated to average 5 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS D-74, Atlanta, GA 30333 ATTN: PRA (0920-0666).  CDC 57.123 v9, 12.0 | | | | | | |

**Antimicrobial Use and Resistance (AUR): Microbiology Laboratory Data**

**Monthly Electronic Upload Specification Tables**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Page 2 of 2 | | | | | | | | | | |
| **Table 3. Antimicrobial Susceptibility Details** | | | | | *These data elements will be transmitted with each month’s report.* | | | | | |
| **Variable Name** | | Description of Variable | | | | | **Examples** | | | |
| antibiotic | | Antibiotic used for susceptibility test | | | | |  | | | |
| PBP2a-agglutination | | PBP2a-agglutination | | | | |  | | | |
| PCRmec-gene | | PCR mec-gene | | | | |  | | | |
| EtestSign | | Etest sign | | | | | >, <, = | | | |
| EtestValue | | Etest value | | | | |  | | | |
| EtestInterp | | Interpretation of Etest | | | | |  | | | |
| MICsign | | MIC sign | | | | |  | | | |
| MICinterp | | Interpretation of the MIC test | | | | |  | | | |
| MICvalue | | MIC value | | | | |  | | | |
| ZoneSign | | Zone sign | | | | |  | | | |
| ZoneInterp | | Interpretation of zone test | | | | |  | | | |
| ZoneValue | | Zone value | | | | |  | | | |
| FinIntrep | | Final interpretation result | | | | |  | | | |
| **Table 3a. List of Antimicrobials used for Susceptibility Testing** | | | | | | | | *This is the list of antimicrobials that will be accepted into NHSN as part of the antimicrobial resistance reporting.* | | |
| Amikacin | | | Cefoxitin | | | Doripenem | | | Meropenem | Rifampin |
| Amoxicillin | | | Ceftaroline | | | Doxycycline | | | Meropenem-vaborbactam | Streptomycin |
| Amoxicillin-clavulanic acid | | | Ceftazidime | | | Ertapenem | | | Micafungin | Streptomycin – high level |
| Ampicillin | | | Ceftazidime/Avibactam | | | Erythromycin | | | Minocycline | Sulfisoxazole |
| Ampicillin-sulbactam | | | Ceftolozane/Tazobactam | | | Fluconazole | | | Moxifloxacin | Tedizolid |
| Anidulafungin | | | Ceftriaxone | | | Fosfomycin | | | Nitrofurantoin | Telavancin |
| Azithromycin | | | Cefuroxime | | | Gemifloxacin | | | Oritavancin | Tetracycline |
| Aztreonam | | | Chloramphenicol | | | Gentamicin | | | Oxacillin | Trimethoprim |
| Caspofungin | | | Ciprofloxacin | | | Gentamicin – high level | | | Penicillin G | Trimethoprim-sulfamethoxazole |
| Cefazolin | | | Clarithromycin | | | Imipenem-cilastatin | | | Penicillin V | Vancomycin |
| Cefepime | | | Clindamycin | | | Imipenem-relebactam with cilastatin | | | Piperacillin-tazobactam | Voriconazole |
| Cefiderocol | | | Colistin | | | Lefamulin | | | Polymyxin B |  |
| Cefotaxime | | | Dalbavancin | | | Levofloxacin | | | Posaconazole |  |
| Cefotetan | | | Daptomycin | | | Linezolid | | | Quinupristin-dalfopristin |  |
| **Table 4. Denominator Data** | | | | *These data elements will be transmitted with each month’s report.* | | | | | | |
| **Variable Name** | **Description of Variable** | | | | | | | | | |
| numAdmissions | Number of admissions | | | | | | | | | |
| numPtDays | Number of inpatient days | | | | | | | | | |
| numEncounters | Number of outpatient encounters | | | | | | | | | |
| noAREvent | No AR Events were identified | | | | | | | | | |